Table 1.
General characteristics of included studies
| Investigators; Year; Study design | Sample size; Mean age in years (range) | Number of drop outs | Female (%) | Systemic conditions | Study groups (n) | Drug used (dosage); Route of administration | Follow‐up (weeks) | Study outcome |
|---|---|---|---|---|---|---|---|---|
| Pradeep et al. 16 2013; RCT | 69; Group 1: NA Group 2: NA (30–50) | Group 1: 6 Group 2: 6 | 46.3 | NA | Group 1: 29 SRP + BP Group 2: 28 placebo + SRP | Group 1: 1% ALN gel (10 mg/mL); topical Group2: placebo gel | Up to 48 | Group 1 showed significantly greater improvements in clinical parameters at follow‐up |
| Sharma and Pradeep 17 2012; RCT | 73; Group 1: NA Group 2: NA (30–50) | Group 1: 5 Group 2: 2 | 46.5 | NA | Group 1: 33 SRP + BP Group 2: 33 placebo + SRP | Group 1: 1% ALN gel (10 mg/mL); topical Group2: placebo gel | Up to 24 | Group 1 showed significantly greater improvements in clinical parameters at follow‐up |
| Sharma and Pradeep 24 2012; RCT | 20; Group 1: NA Group 2: NA (30–50) | Group 1: 1 Group 2: 2 | 40 | NA | Group 1: 9 SRP + BP Group 2: 8 placebo + SRP | Group 1: 1% ALN gel (10 mg/mL); topical Group2: placebo gel | Up to 24 | Group 1 showed significantly greater improvements in clinical parameters at follow‐up |
| Pradeep et al. 25 2012; RCT | 43; Group 1: NA Group 2: NA (30–50) | Group 1: 1 Group 2: 1 | 46.5 | Diabetes mellitus | Group 1: 20 SRP + BP Group 2: 21 placebo + SRP | Group 1: 1% ALN gel (10 mg/mL); topical Group2: placebo gel | Up to 24 | Group 1 showed significantly greater improvements in clinical parameters at follow‐up |
| Graziani et al. 18 2009; RCT | 60; Group 1: 44.7 Group 2: 42.2 (NA) | Group 1: 5 Group 2: 4 | 65 | NA | Group 1: 30 SRP + BP Group 2: 30 SRP | Group 1: Once weekly NE (12.5 mg/intramuscular) / 12 times; systemic | Up to 24 | Improvements in clinical parameters for both groups at follow‐up were comparable |
| Lane et al. 26 2005; RCT | 70; Group 1: 48.2 Group 2: 46.8 (NA) | Group 1: 2 Group 2: 2 | 43.9 | NA | Group 1: 41 SRP + BP Group 2: 25 placebo + SRP | Group 1: ALN (10 mg/day) or RSD 5 mg/day + calcium citrate 1000 mg/day + Vitamin D3; oral Group 2: placebo + calcium citrate 1000 mg/day + Vitamin D3/oral | Up to 48 | Improvements in clinical parameters for both groups at follow‐up were comparable |
| Rocha et al. 27 2004; RCT | 40; Group 1: 57.8 Group 2: 58.0 (55–65) | Group 1: 0 Group 2: 0 | 100 | Obese/overweight; menopause | Group 1: 20 SRP + BP Group 2: 20 placebo + SRP | Group 1: ALN (10 mg/day); oral | Up to 24 | Group 1 showed significantly greater improvements in clinical parameters at follow‐up |
| Rocha et al. 28 2001; RCT | 40; Group 1: 56.0 Group 2: 55.0 (50–60) | Group 1: 0 Group 2: 0 | 50 | Diabetes mellitus; menopause | Group 1: 20 SRP + BP Group 2: 20 placebo + SRP | Group 1: ALN (10 mg/day); oral Group 2: trivitamin preparation (thiamin 100 mg + pyridoxine 50 mg + cyanocobalamin 250 g) | Up to 24 | Group 1 showed significantly greater improvements in clinical parameters at follow‐up |
RCT, randomized clinical trial; SRP, scaling and root planing; BP, bisphosphonates; ALN, alendronate; RSD, risedronate; NE, neridronic acid; NA, not available.